About the Company
We do not have any company description for CURIS INC at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on CURIS INC
Curis Provides Second Quarter 2025 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, ...
Curis, Inc. (NASDAQ:CRIS) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 5, 2025 Curis, Inc. beats earnings expectations. Reported EPS is $-0.68049, ...
Curis Inc (CRIS) Q2 2025 Earnings Report Preview: What To Expect
Curis Inc (NASDAQ:CRIS) is set to release its Q2 2025 earnings on Aug 5, 2025. The consensus estimate for Q2 2025 revenue is $2.64 million, and the earnings are expected to come in at -$1.36 per share ...
Curis Announces $7.0 Million Registered Direct and Concurrent Private ...
--Curis, Inc., a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive ...
Curis Files Prospectus Supplement for Stock Offering
Curis ( (CRIS) ) has provided an update. On August 8, 2025, Curis, Inc. announced the filing of a prospectus supplement under its universal shelf registration statement with the SEC, allowing for the ...
Curis Announces $12.1 Million Registered Direct and Concurrent Private ...
Gross proceeds to Curis from the offering are expected to be approximately $12.1 million, before deducting the placement agents' fees and other offering expenses payable by Curis.
Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination ...
LEXINGTON, Mass., Feb. 9, 2021 /PRNewswire/ — Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ...
Curis Inc Q4 sales decline - Markets Insider
(RTTNews) - Curis Inc (CRIS) announced Loss for fourth quarter of -$11.71 million The company's bottom line came in at -$11.71 million, or -$2.03 per share. This compares with -$11.33 million, or ...
Curis Reports Updated Data in Two Abstracts for CA-4948 Accepted for ...
LEXINGTON, Mass., May 12, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today ...
Curis settles with Micromet, to receive $2.5M - MarketWatch
NEW YORK (MarketWatch) -- Curis Inc. said it will receive a $2.5 million payment from Micromet as part of a settlement of their payments dispute.
Curis withdraws from 2 drug development projects - MarketWatch
Curis, based in Cambridge, Mass., said it has spent about $8.4 million in co-development costs under the basal cell carcinoma program. The decision to withdraw from the project doesn't affect ...
Similar Companies
Loading the latest forecasts...